26 results about "Myocardial tissue" patented technology

A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

A catheter utilizes a distal electrode array configured for quantification of endocardial or epicardial propagation velocity, with electrodes defining approximately equilateral triangles, such that the calculated velocity can be approximated regardless of the wave front direction. The distal electrode array can also include resilient splines carrying the electrodes such that the splines can deform to ensure contact between the electrodes and the heart tissue. Additionally, the electrodes of the distal electrode array can be individually addressable. Bipolar ablation lines or boxes can also be implemented using two parallel catheters at the endocardium and at the epicardium. Certain configurations include one or more distal electrode arrays of sufficient size to span an entire ventricular tachycardia (VT) circuit. The catheter may also be configured to detect block lines by pacing from edge pacing electrodes of the distal electrode array, and / or to detect fiber orientation by pacing from several edge pacing electrodes.

This application relates to the field of finite element analysis technology, and in particular to a method and related apparatus for generating finite element meshes based on myocardial tissue pathological slices. The method includes: extracting spatial features from myocardial tissue pathological slice images to obtain intermediate layer features; inputting each image patch into a Transformer module to obtain hidden features; concatenating the hidden features with the intermediate layer features to obtain semantic segmentation results; determining a tissue category prediction mask; determining the tissue category; extracting the contour edge pixel regions of each tissue and generating a multi-category comprehensive mask image; and performing label recognition on the multi-category comprehensive mask image to generate finite element meshes with different material properties. This application enables effective and accurate analysis of key functional microstructures, eliminating the cumbersome process of manually converting histological slices into finite element geometry and meshes, which is highly dependent on traditional methods, thus laying a solid foundation for computational modeling simulation and microstructure analysis.

The present application relates to the technical field of image fusion, and discloses a heart failure follow-up data visualization processing method based on multi-modal image fusion, comprising the following steps: constructing a left ventricular fiber direction field and extracting fusion scalar data along the fiber path, establishing an isochronous scalar complex quantification model for describing the change pattern of activation time in the fiber direction, and taking the model as a continuous control variable to participate in subsequent filtering, reconstruction and visualization coding processes. The method completes the structured arrangement of the scalar data along the integral path of the fiber, so that the fusion data is more consistent with the propagation law of the myocardial tissue when outputting the polar coordinate graph and the three-dimensional ventricular coloring graph, and can visually inhibit and prompt the local non-continuous fluctuation.

This application relates to a coronary sinus and left atrium shunt system, belonging to the field of medical device technology. The system described in this application, by setting up a puncture component and a shunt component including a cutter, allows for the cutting of a portion of myocardial tissue between the coronary sinus and the left atrium, forming a shunt orifice. This establishes a shunt channel between the coronary sinus and the left atrium, effectively avoiding the embolism risk associated with atrial septal shunts and improving coronary artery blood perfusion, potentially benefiting myocardial recovery.

This invention discloses a medical repair hydrogel and its preparation method, specifically relating to the field of biomedical engineering technology. The hydrogel is a three-dimensional network structure formed by the synergistic self-assembly of glycyrrhizic acid and polydipsia glycoside through non-covalent bonds such as hydrogen bonding, hydrophobic interactions, and π-π stacking. No chemical cross-linking agent is required. It spontaneously forms a hydrogel upon heating to 70°C until completely dissolved and then cooling. It possesses reactive oxygen species-responsive structural dissociation characteristics, mechanical properties adapted to myocardial tissue, and a controllable degradation rate. This invention is suitable for intramyocardial drug administration after PCI, avoiding the shortcomings of traditional synthetic hydrogels that require external triggering and have unsuitable gelation conditions. Simultaneously, its three-dimensional network structure enables simultaneous long-term sustained release of the two active ingredients, with a 24-hour burst release rate of less than 25% and a cumulative release rate exceeding 70% within 7 days. This solves the problem of short half-lives and rapid clearance by body fluids of small molecule drugs, achieving continuous drug delivery to the lesion site.

The embodiment of the application relates to the technical field of medical coating materials, and particularly relates to a method for forming an active coating on the surface of a degradable occlusion device and the degradable occlusion device, the method comprising the following steps: preparing perfluorohexane liposomes loaded with stromal cell-derived factor-1 alpha (SDF-1 alpha); preparing polylactic acid-glycolic acid copolymer@rapamycin@nitric oxide donor nanoparticles; preparing a methacrylated gelatin-tannic acid hydrogel carrier; mixing the liposomes and the nanoparticles into the hydrogel carrier; soaking the degradable occlusion device in the mixture obtained in the previous step, and performing light crosslinking treatment on the mixture, so that an active coating is formed on the surface of the degradable occlusion device. Therefore, comprehensive consideration of "endothelialization repair in the early implantation period - myocardial tissue remodeling after implantation" is realized, controllable time-sequencing repair of the degradable occlusion device on the heart defect site is ensured, and the endogenous functional repair effect of the heart of a patient is improved.

The application discloses application of recombinant human USP13 protein in preparation of a drug for treating diabetic cardiomyopathy, and belongs to the technical field of biological medicines.The application first proves that the expression of USP13 in myocardial tissue and serum is significantly reduced under the condition of diabetic cardiomyopathy (DCM); the recombinant human USP13 protein can obviously reduce the level of myocardial cell active oxygen, reduce the expression of NLRP3 inflammasome and active Caspase3 protein in a DCM in-vitro model induced by high sugar / palmitic acid; in a DCM mouse model injected with the recombinant human USP13 protein through a tail vein, myocardial cell apoptosis is inhibited, and the expression of NLRP3 inflammasome and the synthesis of TNF-alpha in the heart of the animal are reduced.USP13 is a human protein, has no obvious toxic side effects, is high in safety, is small in immunological rejection in theory, provides a new effective drug for the clinical treatment of DCM, and has important clinical application value and industrialization prospect.

The application belongs to the technical field of biological nanomaterials, and particularly relates to a nano-enzyme material and a preparation method and application thereof. The application reacts dimethyl imidazole and metal salt in an aqueous solution to obtain a metal-dimethyl imidazole composite material solution, wherein the metal salt comprises copper salt and / or zinc salt; and reacts the metal-dimethyl imidazole composite material solution and tannic acid to obtain a nano-enzyme material. The nano-enzyme material provided by the application has excellent antioxidant enzyme-like catalytic activity and good biocompatibility, can effectively remove abnormally increased reactive oxygen species (ROS) in the process of myocardial infarction and myocardial ischemia-reperfusion injury, inhibit inflammatory response and myocardial cell apoptosis, improve the mitochondrial function state, thereby promoting the repair of damaged myocardial tissue and significantly improving the cardiac function, and provides a new technical solution for the treatment of myocardial infarction and related ischemic cardiovascular diseases.

The invention discloses an application of a Lamp2b-IMTP fusion exosome in treatment of coronary heart disease. The specific application method comprises the following steps: preparing an exosome matrix, carrying out optimization treatment on the exosome matrix, and finally, specifically combining the optimized exosome matrix with myocardial cells through IMTP on the surface of the Lamp2b-IMTP fusion exosome in an intravenous injection administration mode. Therapeutic substances are accurately delivered to damaged myocardial tissues, which is the core advantage of the fused exosome and is also the basis of subsequent treatment effects: IMTP (myocardial targeting peptide) is modified on the surface of the exosome, and the IMTP can be accurately combined with a specific receptor on the surface of a damaged myocardial cell.

This invention provides the use of a reagent overexpressing Parp7 in the preparation of drugs for treating septic cardiomyopathy, belonging to the field of biomedical technology. This invention involves constructing a recombinant adeno-associated virus vector AAV9-F4 / 80- that specifically overexpresses PARP7 on macrophages. Parp7 The drug was intravenously injected into mice, and a septic cardiomyopathy model was established using lipopolysaccharide induction. Experimental results showed that macrophage-specific overexpression of PARP7 significantly reduced serum levels of myocardial injury markers CK-MB and cTnT, improved cardiac function indicators such as ejection fraction and fractional shortening, alleviated myocardial tissue pathological damage, and inhibited macrophage infiltration and inflammatory factors. Ifn-beta , Tnf- α , Il‑6 and Il‑1β The expression of PARP7. This invention reveals the protective role of PARP7 in septic cardiomyopathy, providing a new target and strategy for the treatment of septic cardiomyopathy.

This application discloses the use of Qi Xue Kang oral liquid in the preparation of drugs for the prevention or treatment of myocardial ischemia-reperfusion injury. The first aspect of this application discloses the use of Qi Xue Kang oral liquid in the preparation of drugs for the prevention or treatment of myocardial ischemia-reperfusion injury. Experiments have shown that its application in treating myocardial ischemia-reperfusion injury has better therapeutic effects compared to drugs such as Qi Shen Yi Qi Dripping Pills, significantly reducing the expression levels of myocardial injury markers, showing more pronounced pathological changes in myocardial tissue, and significantly improving the number of cardiomyocyte apoptosis.

This invention relates to the field of biomedical technology. It provides a cardiac-targeting bispecific antibody protein and its applications. The bispecific antibody protein comprises a targeting conjugate that specifically recognizes NPR1 and a sequence that specifically recognizes GDF15. The amino acid sequence of the bispecific antibody protein is shown in SEQ ID NO.2. This invention cleverly achieves the dual functions of cardiac tissue targeting and effectively mediating endocytosis by utilizing a membrane protein specifically highly expressed in myocardial tissue as an effector molecule. The cardiac-targeting bispecific antibody protein of this invention can target the cardiac tissue surface receptor NPR1 and specifically target and degrade GDF15 within cardiac tissue, showing promising application prospects in the treatment of heart failure.

An injectable hydrogel for heart failure treatment with myocardial tissue repair function and its preparation method and use are disclosed. The hydrogel is prepared by chelating alginic acid and multivalent cations. The hydrogel is loaded with an active substance for repairing cardiac injury. The active substance is recombinant humanized collagen type III. The hydrogel is administrated into the left ventricle free wall by transendocardial injection. Implanting the hydrogel in the myocardium can increase the thickness of the left ventricular wall, adjust the stress of the ventricular wall, affect the morphology of the left ventricle, and prevent or reverse left ventricular enlargement. Further, the hydrogel is loaded with a new recombinant humanized collagen material that has the function of repairing cardiac tissue injury to further improve cardiac function and promote cardiac repair.

This invention discloses the use and preparation method of a compound or a pharmaceutically acceptable salt or solvate thereof in the preparation of a drug for the prevention and / or treatment of myocardial injury and / or inflammation. Specifically, it discloses the use of a compound having the structure shown in Formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a drug for the prevention and / or treatment of myocardial injury and / or inflammation. The drug formed by this compound can effectively alleviate myocardial and endothelial cell damage, reduce inflammatory response, improve cardiac function, reduce pathological damage to myocardial tissue, decrease the expression levels of heart failure markers (NT-proBNP) and inflammation-related markers (TNF-α, IL-6), and promote angiogenesis and maturation. (I)

The application discloses application of piRNA-AMIPIR in preparation of a drug for improving heart injury after acute myocardial infarction. The application first discovers that piRNA-AMIPIR is highly expressed in myocardial tissue after acute myocardial infarction (MI), and the expression level is positively correlated with the myocardial injury degree. After administration of the antisense nucleotide Antagomir-AMIPIR designed based on the piRNA-AMIPIR in a mouse acute myocardial infarction model, the myocardial cell apoptosis is reduced, the active oxygen (ROS) accumulation is reduced, the inflammatory cell infiltration is inhibited, the heart contraction function is significantly improved, and the ischemia-induced heart injury is reduced. The application confirms the potential value of the piRNA-AMIPIR as a treatment target for heart injury after acute myocardial infarction, the antisense nucleotide provides a new candidate drug and treatment strategy for clinical treatment of acute myocardial infarction, and has important scientific research significance and clinical application prospect.

Described herein are new methods and compositions for preventing, treating and / or ameliorating cardiac diseases, cardiac disorders, myocardial tissue damage, pulmonary diseases and / or pulmonary disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure.

This invention discloses a drug for viral myocarditis, relating to the field of drug preparation technology. The drug comprises at least one of imperatorin, isochorin, and epicatechin gallate. This drug can effectively inhibit viral replication in myocardial tissue, significantly reduce serum pro-inflammatory factor levels, alleviate inflammatory infiltration, and significantly reduce cell apoptosis, thereby exerting a therapeutic effect on viral myocarditis. This invention solves the problem of the lack of highly effective multi-target viral myocarditis drugs in the prior art.

The application discloses a kind of high-flux myocardial tissue μN level contractility fiber grating sensors, it is characterized in that, including several sensing units, each sensing unit includes pedestal and fiber segment, the fiber segment between different sensing units is sequentially connected in head and tail;Wherein the pedestal is hollow structure, the both ends of fiber segment are fixed to the side of pedestal, the middle part of fiber segment is fixed to the other side of pedestal, so that the part of fiber segment passing through the hollow area of pedestal forms a pair of parallel suspended intervals;Fiber grating is provided on the suspended interval of one side of fiber segment, the radius of the suspended interval of fiber grating in fiber segment is less than the radius of the rest of fiber segment, fiber grating is provided with first grid area and second grid area, and the radius of first grid area and second grid area is not identical.The sensor can realize real-time distributed monitoring of myocardial tissue, and can realize temperature self-compensation, simple structure, high precision.

This invention relates to the field of cardiac electrophysiological simulation technology, specifically to simulation methods, devices, equipment, and media for analyzing ventricular arrhythmias. The invention first sets the ion channel conductivity parameters of the heart under pathological conditions, then calculates the total ion current generated by the lesion based on these parameters, and simultaneously sets the myocardial tissue conductivity caused by the lesion. The cardiac geometry, initial membrane potential, and the set ion channel conductivity parameters, total ion current, and myocardial tissue conductivity are substituted into a Bidomain model to solve for the cardiac transmembrane potential and intracellular / extracellular potential. Based on these potentials, the invention analyzes whether the aforementioned lesions will induce ventricular arrhythmias. This invention has the ability to simulate a wide range of pathological scenarios, effectively reducing the limitations of existing medical diagnostic methods in analyzing the mechanisms of arrhythmia.

The application discloses application of raloxifene or a pharmaceutical salt thereof in preparation of a medicine for treating sepsis cardiomyopathy, and simultaneously discloses application of a STAT3 protein Tyr705 site as a sepsis cardiomyopathy treatment target, and belongs to the technical field of biological medicines. The application proves through in-vivo and in-vitro experiments that raloxifene can effectively improve body temperature drop and left ventricular systolic function reduction related to sepsis cardiomyopathy, reduce myocardial inflammatory infiltration, relieve myocardial oxidative stress, mitochondrial dysfunction and energy metabolism disorder, and play a definite myocardial protection role by inhibiting phosphorylation activation of the STAT3 protein Tyr705 site in myocardial tissue and cells. The application provides a novel targeted treatment strategy and drug selection for sepsis cardiomyopathy, and has a good clinical transformation application prospect.

The application discloses a kind of nanoliposome materials and its preparation method and preparation treatment sepsis cardiomyopathy drug application, nanoliposome material includes the following mass percentage of components: soybean phosphatidylcholine 60~70%;Cholesterol 20~30%;DSPE-PEG-PCM 2~3%;DSPE-PEG-TAT 1~2%;Xiong Zhosu 1~5%.Wherein, Xiong Zhosu is loaded in nanoliposome material.Meanwhile, nanoliposome material is formed stable nanoliposome drug delivery system by soybean phosphatidylcholine, cholesterol, DSPE-PEG-PCM, DSPE-PEG-TAT and Xiong Zhosu.The nanoliposome is mainly composed of soybean phosphatidylcholine, supplemented with cholesterol, to form a stable lipid bilayer structure, so as to effectively load active ingredient Xiong Zhosu, protect it from body fluid degradation.To enhance the targeting of the drug, the surface of the nanoliposome material is modified with DSPE-PEG-PCM and DSPE-PEG-TAT, and through the double modification strategy, the effective concentration and distribution uniformity of the drug in myocardial tissue can be significantly improved.

A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.

The application discloses application of SGC707 in preparation of anti-myocardial fibrosis drugs and belongs to the technical field of medicines.The experiment verifies that SGC707 can significantly reduce myocardial tissue collagen deposition of mice caused by ISO, obviously relieve the increase of mRNA expression levels of alpha-SMA, TGF-beta, PRMT3, p53 and PAI-1 caused by ISO, has the function of slowing down myocardial fibrosis, has important clinical guiding significance for treating myocardial fibrosis and provides a new way for exploring development of low-toxicity and high-efficiency anti-myocardial fibrosis drugs.